AbbVie (ABBV), Abbott (ABT) Win Dismissal of AndroGel, Humira Racketeering Suit
Get Alerts ABBV Hot Sheet
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 3.8%
Revenue Growth %: -2.1%
Join SI Premium – FREE
AbbVie (NYSE: ABBV) and Abbott Labs (NYSE: ABT) won a lawsuit over claims of racketeering with respect to the Humira arthritis drug and AndroGel testosterone drug.
According to Reuters, U.S. District Judge Robert Dow said the New England Carpenters Health and Welfare Fund didn't show that AbbVie and Abbott joined together
with retail pharmacies and intermediaries to maximize sales of the two drugs.
There will still be litigation with respect to remaining state law claims in the suit, which Dow said he might not have jurisdiction over.
Sales of Humira and AndroGel were $5.93 billion and $472 million for the first-half of 2014.
AbbVie and Abbott are flat in early trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: working with AbbVie (ABBV) to identify, investigate and remove suspected counterfeit Botox products found in the US
- Evaxion Biotech (EVAX) Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
- atai Life Sciences (ATAI) Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
Create E-mail Alert Related Categories
FDA, Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!